Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026
– ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction –
– ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction –